Long-term outcomes of antipsychotic medication use in veterans with ptsd

The Defense Health Agency has awarded a $1.632 million Project Grant to the Ocean State Research Institute, Inc., a non-profit research organization, to investigate the long-term outcomes of antipsychotic medication use in U.S. veterans with post-traumatic stress disorder (PTSD). This grant, funded through the Military Medical Research and Development program (CFDA 12.420), supports basic, applied, and advanced biomedical research to transform healthcare for service members and the public.

As the prime awardee, Ocean State Research Institute will lead this 4-year study examining the long-term effects of antipsychotic medications used to treat PTSD in veterans. In addition, as a subrecipient on prior federal grants, Ocean State Research Institute has partnered with universities like Yale, Duke, and Oregon Health and Science to participate in multi-site trials, provide study coordination, analyze deployment and health data, and guide veterans' pain management programs. Their past subaward work has focused on areas such as suicide risk factors, substance misuse screening, COVID-19 testing solutions, and cardiopulmonary vascular biology.